DNA topoisomerase-targeting antitumor agents and drug resistance.
about
Different susceptibilities of postmitotic checkpoint-proficient and -deficient Balb / 3T3 cells to ICRF-193, a catalytic inhibitor of DNA topoisomerase II.Mechanisms regulating resistance to inhibitors of topoisomerase II.Y-box binding protein 1 enhances DNA topoisomerase 1 activity and sensitivity to camptothecin via direct interaction.Identification of genetic changes associated with drug resistance by reverse in situ hybridizationCPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues.A "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone.Human topoisomerase II-alpha is highly expressed in sinonasal-inverted papilloma, but not in inflammatory polyp.Establishment and characterization of 6-[[2-(Dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one dihydrochloride (TAS-103)-resistant cell lines.Overexpression of multidrug resistance protein gene in human cancer cell lines selected for drug resistance to epipodophyllotoxins.Non-P-glycoprotein-mediated atypical multidrug resistance in a human bladder cancer cell line.Expression of topoisomerase II alpha and beta in an adenocarcinoma cell line carrying amplified topoisomerase II alpha and retinoic acid receptor alpha genes.Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell linesIncidence of mutation and deletion in topoisomerase II alpha mRNA of etoposide and mAMSA-resistant cell lines.Gene mutation analysis and quantitation of DNA topoisomerase I in previously untreated non-small cell lung carcinomas.Biomodulation by hyperthermia of topoisomerase II-targeting drugs in human colorectal cancer cells.The multidrug resistance-associated protein gene confers drug resistance in human gastric and colon cancers.
P2860
Q32063207-F63D9E6A-6063-4017-A72F-F67E97AF3533Q34361770-04C79551-BEBB-4675-95D9-35F6869D450EQ35021157-889E59C7-D64D-4D49-8202-FEE4CDD45A9BQ36116003-1FA7F443-226E-4AD0-B4B8-0B068BF34BC6Q36617921-6ACB6723-3B9A-4C84-A234-1E3AB2D2C517Q37204002-69AE17BB-E2F8-490C-AD2C-1E4E02E69279Q37568706-A8AA7A41-F681-450B-BF2B-77BC14A1E770Q40876344-8AD89710-CBC5-416F-A919-5768C2AE0AC4Q41189277-728BAFE9-06D2-4B1E-8DB7-CE74EF4319AEQ41276203-AF58CC8E-7330-4D1D-8DB6-23FB2B44F88DQ41522535-C67B9EE6-C250-487A-9120-F239785CC1D6Q42281033-214914F3-DEC3-451D-ACBF-0BB0E6C626B3Q43777040-43CF0607-A51C-4FA2-8D64-B9957FB41428Q48054186-09E958E9-3028-466A-8686-C1A1283EC8DCQ54158839-5119F9EF-71FC-4835-84E0-A49F50EB20C6Q55098643-E1223F06-D192-4771-8E87-E06090C84690
P2860
DNA topoisomerase-targeting antitumor agents and drug resistance.
description
1992 nî lūn-bûn
@nan
1992 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
DNA topoisomerase-targeting antitumor agents and drug resistance.
@ast
DNA topoisomerase-targeting antitumor agents and drug resistance.
@en
type
label
DNA topoisomerase-targeting antitumor agents and drug resistance.
@ast
DNA topoisomerase-targeting antitumor agents and drug resistance.
@en
prefLabel
DNA topoisomerase-targeting antitumor agents and drug resistance.
@ast
DNA topoisomerase-targeting antitumor agents and drug resistance.
@en
P2093
P1433
P1476
DNA topoisomerase-targeting antitumor agents and drug resistance.
@en
P2093
P304
P577
1992-08-01T00:00:00Z